WebJun 19, 2024 · Informa’s new Trials and Drugs APIs will enable users to search or stream information directly from Citeline’s R&D Intelligence databases into their own systems and embed Informa’s quality datasets directly into their own organization’s data and workflows, minimizing duplicated effort and time spent acquiring and manipulating data. WebMar 24, 2024 · The 2024 report assesses industry trends by examining the pharmaceutical pipeline by company, therapeutic area, disease, target, and drug type, using data from Pharma Intelligence’s Pharmaprojects, part of the Citeline suite of products, which has been tracking global drug development since 1980.
Drug Discovery Websites and Databases - Drug Hunter
WebResponse from Citeline editorial team In Pharmaprojects, Global Status is the highest status achieved by the drug in any indication that is being pursued by a commercial entity. Ganetespib is in Phase II of development for mesothelioma and ovarian cancer. Trials described as “Phase I/II” are designated as Phase II in Pharmaprojects. WebCiteline Inc. provides clinical trial intelligence solutions for real-time research and development for the pharmaceutical industry worldwide. Its solutions include Trialtrove that tracks global clinical trials in real-time; Trialpredict to forecast clinical trial timings; Pharmaprojects that provides access to various drug profiles; Sitetrove to imy stand for text
Citeline l Data Analysis Pharma Intelligence - Informa
WebOct 21, 2024 · The third quarterly report of 2024 from ASGCT and Citeline (formerly Informa Pharma Intelligence) is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more. Approval of two gene therapies in the EU and two more in the U.S. WebOct 11, 2024 · Pipeline information was reconstructed using Citeline Pharmaprojects. Additional projects mentioned only on company websites were included manually. For comparison, across the top 20 pharmaceutical companies, there are approximately 580 ongoing biologics R&D programs and assets. AI-native biologics companies today thus … imy text